Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the USMadhav KC, Michaela A. Dinan, Terry Hyslop et al.|JAMA Network Open|2023Cited by 45
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast CancerSara A. Hurvitz, Amanda Gillespie-Twardy, Rachel M. Layman et al.|Journal of Clinical Oncology|2026Cited by 4
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0
Supplementary Table from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBCJulia Foldi, Lajos Pusztai, Adriana Kahn et al.|Unknown|2023Cited by 0
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0